Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1641 1642 1644 1684
This examiner grants 57% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18286955 | Glycan Targets of Serum IgG and IgM Antibodies | Non-Final OA | REGENTS OF THE UNIVERSITY OF MINNESOTA |
| 17185469 | METHOD FOR PREDICTING THE OUTCOME OF A TREATMENT WITH AFLIBERCEPT OF A PATIENT SUSPECTED TO SUFFER FROM A CANCER BY MEASURING THE LEVEL OF A PLASMA BIOMARKER | Non-Final OA | SANOFI |
| 17780407 | COMPOSITIONS AND METHODS FOR EPITOPE SCANNING | Non-Final OA | The Brigham and Women's Hospital, Inc. |
| 18559910 | MODIFIED FCRN BINDING FRAGMENTS WITH IMPROVED HALF-LIFE | Non-Final OA | MedImmune, LLC |
| 17626616 | TREATMENT OF DISEASES ASSOCIATED WITH PROTEIN MISFOLDING BY NERVOUS SYSTEM EXPRESSION OF AN ENZYME WHICH HAS A DEOXYRIBONUCLEASE (DNase) ACTIVITY | Final Rejection | CLS THERAPEUTICS LIMITED |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy